Bayer (BAYRY)
(Delayed Data from OTC)
$7.07 USD
+0.02 (0.28%)
Updated Jul 5, 2024 03:59 PM ET
3-Hold of 5 3
B Value D Growth D Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BAYRY 7.07 +0.02(0.28%)
Will BAYRY be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BAYRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BAYRY
Regeneron (REGN) Gets Positive CHMP Opinion for Lymphoma Drug
Bayer's (BAYRY) AskBio Advances Parkinson Disease Study
BAYRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regeneron (REGN) Outperforms Industry YTD: What Lies Ahead?
Regeneron (REGN) Announces Positive Data on Oncology Candidate
Pharma Stock Roundup: BAYRY's Q1 Earnings, JNJ's New Buyout, Pipeline Updates
Other News for BAYRY
Covestro unveils cost cuts amid UAE energy firm takeover talks
Warning: BAYRY is at high risk of cutting its dividend
Ocular Therapeutix jumps after investor day updates
Archer Daniels, Bayer extend farming collaboration
AstraZeneca dominates, Merck’s Keytruda beaten as ASCO 2024 concludes